SK Biopharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Dong Hoon Lee
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.9yrs |
| CEO ownership | 0.004% |
| Management average tenure | no data |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
SK Biopharmaceuticals Co., Ltd. (KRX:326030) Shares Could Be 47% Below Their Intrinsic Value Estimate
Nov 27
There May Be Underlying Issues With The Quality Of SK Biopharmaceuticals' (KRX:326030) Earnings
Aug 22SK Biopharmaceuticals Co., Ltd. (KRX:326030) Looks Just Right With A 25% Price Jump
Aug 21Does This Valuation Of SK Biopharmaceuticals Co., Ltd. (KRX:326030) Imply Investors Are Overpaying?
May 22SK Biopharmaceuticals Co., Ltd. (KRX:326030) Not Lagging Industry On Growth Or Pricing
Apr 09Is SK Biopharmaceuticals (KRX:326030) A Risky Investment?
Feb 27CEO
Dong Hoon Lee (56 yo)
2.9yrs
Tenure
Mr. Dong Hoon Lee serves as Chief Executive Officer of SK Biopharmaceuticals Co., Ltd. since 2022 and also served as its Chairman of the Board since February 26, 2020. He is President of SK Biopharmaceutic...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 4.8yrs | no data | 0.0038% ₩ 333.2m | |
| CFO & Executive Director | less than a year | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Director | 1.8yrs | no data | no data | |
| Independent Chairman of the Board | 5.3yrs | no data | no data | |
| Chairman of the Scientific Advisory Board | 1.3yrs | no data | no data | |
| Independent Outside Director | 5.3yrs | no data | no data |
3.3yrs
Average Tenure
Experienced Board: A326030's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 14:45 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SK Biopharmaceuticals Co., Ltd. is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dae Woong Yoo | Bookook Securities Co. Ltd |
| Seohyun Lee | Citigroup Inc |
| Sunghwan Kim | Credit Suisse |